The reiteration of a Buy rating and maintenance of a $9 price target by a reputable analyst like Raghuram Selvaraju from HC Wainwright & Co. is a strong positive signal for Aquestive Therapeutics. This endorsement likely reflects confidence in the company's future performance and growth prospects, which could positively influence investor sentiment and potentially drive up the stock price in the short term.